<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yan L</submitter><funding>NCATS NIH HHS</funding><funding>Howard Hughes Medical Institute</funding><funding>NHLBI NIH HHS</funding><pagination>1399-411</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4108264</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>34(7)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>S100A12 and fibroblast growth factor 23 are biomarkers of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). We tested the hypothesis that human S100/calgranulin would accelerate cardiovascular disease in mice subjected to CKD.&lt;h4>Approach and results&lt;/h4>A bacterial artificial chromosome of the human S100/calgranulin gene cluster containing the genes and regulatory elements for S100A8, S100A9, and S100A12 was expressed in C57BL/6J mouse (hBAC-S100) to generate a novel humanized mouse model. CKD was induced by ureteral ligation, and hBAC-S100 mice and wild-type mice were studied after 10 weeks of chronic uremia. hBAC-S100 mice with CKD showed increased fibroblast growth factor 23 in the hearts, left ventricular hypertrophy, diastolic dys</pubmed_abstract><journal>Arteriosclerosis, thrombosis, and vascular biology</journal><pubmed_title>S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.</pubmed_title><pmcid>PMC4108264</pmcid><funding_grant_id>1R01HL4821</funding_grant_id><funding_grant_id>UL1 TR000430</funding_grant_id><funding_grant_id>R01 HL114821</funding_grant_id><pubmed_authors>Yan L</pubmed_authors><pubmed_authors>Earley J</pubmed_authors><pubmed_authors>Puri TS</pubmed_authors><pubmed_authors>Hofmann Bowman MA</pubmed_authors><pubmed_authors>Mathew L</pubmed_authors><pubmed_authors>Gardner B</pubmed_authors><pubmed_authors>Chellan B</pubmed_authors></additional><is_claimable>false</is_claimable><name>S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.</name><description>&lt;h4>Objective&lt;/h4>S100A12 and fibroblast growth factor 23 are biomarkers of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). We tested the hypothesis that human S100/calgranulin would accelerate cardiovascular disease in mice subjected to CKD.&lt;h4>Approach and results&lt;/h4>A bacterial artificial chromosome of the human S100/calgranulin gene cluster containing the genes and regulatory elements for S100A8, S100A9, and S100A12 was expressed in C57BL/6J mouse (hBAC-S100) to generate a novel humanized mouse model. CKD was induced by ureteral ligation, and hBAC-S100 mice and wild-type mice were studied after 10 weeks of chronic uremia. hBAC-S100 mice with CKD showed increased fibroblast growth factor 23 in the hearts, left ventricular hypertrophy, diastolic dys</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Jul</publication><modification>2025-04-19T04:55:59.033Z</modification><creation>2019-03-27T01:32:38Z</creation></dates><accession>S-EPMC4108264</accession><cross_references><pubmed>24855059</pubmed><doi>10.1161/ATVBAHA.114.303508</doi><doi>10.1161/atvbaha.114.303508</doi></cross_references></HashMap>